Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) announced a second program with a leading Active Pharmaceutical Ingredient (API) manufacturer to develop a more sustainable and cost-effective manufacturing route for a large-volume ingredient.
The company highlighted that this program follows an earlier collaboration between the two parties, announced on January 31, 2024. Under the first program, Willow has already achieved certain development goals.
The collaboration partner has now engaged Willow to develop an enzyme to replace an existing complex large-scale chemical process.
The development phase of the funded collaboration is expected to last six months. Additional milestone payments can be achieved for hitting defined performance targets as early as 2025.
It marks Willow’s fourth commercial agreement announced in 2024 that contains milestone or other commercial payments which could be achieved as soon as next year.
"We are excited to start a second program with this leading API manufacturer to apply our technology platform to the production of more sustainable APIs for existing, large volume global markets," Willow Biosciences CEO Dr Chris Savile said in a statement.
"The ultimate goal of any successful business is to establish a long-term relationship with its partners.”